Reneuron Gp (RNUGF) Upgraded to Buy at Zacks Investment Research

Reneuron Gp (OTCMKTS:RNUGF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Friday.

According to Zacks, “ReNeuron Group plc is involved in the development of cell-based therapies. Its therapeutic candidate is CTX stem cell therapy for the treatment of patients left disabled by the effects of a stroke which are in clinical development phase. ReNeuron Group plc is headquartered in Pencoed, the United Kingdom. “

Shares of Reneuron Gp (OTCMKTS RNUGF) opened at $0.02 on Friday. Reneuron Gp has a 52 week low of $0.02 and a 52 week high of $0.05.

TRADEMARK VIOLATION WARNING: “Reneuron Gp (RNUGF) Upgraded to Buy at Zacks Investment Research” was published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.com-unik.info/2018/01/12/reneuron-gp-rnugf-upgraded-to-buy-at-zacks-investment-research.html.

About Reneuron Gp

ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company’s lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase III clinical trial for the treatment of patients left disabled by the effects of a stroke, as well as that has been completed Phase I clinical trial to treat critical limb ischaemia, a side effect of diabetes.

Get a free copy of the Zacks research report on Reneuron Gp (RNUGF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Reneuron Gp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reneuron Gp and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit